Literature DB >> 8482293

Intravenous immunoglobulin in two children with Guillain-Barré syndrome.

L D Notarangelo1, M Duse, S Tiberti, B Guarneri, A Brunori, A Negrini, A G Ugazio.   

Abstract

Two children with Guillain-Barrè syndrome were successfully treated with high-dose intravenous immunoglobulin (IVIG) and no relapses occurred over a 1 year follow up. No side-effects were observed. These data provide further evidence that IVIG may be safely and effectively employed in children with Guillain-Barrè syndrome.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8482293     DOI： 10.1007/bf01956757

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  14 in total

1.  Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome.

Authors:  E Shahar; E G Murphy; C M Roifman
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

2.  [A case of Guillain-Barré syndrome treated with intravenous high doses of immunoglobulins].

Authors:  G Mauro
Journal:  Rev Neurol (Paris)       Date:  1989       Impact factor: 2.607

3.  Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin.

Authors:  Y Sultan; M D Kazatchkine; P Maisonneuve; U E Nydegger
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

4.  Effect of intravenous immunoglobulin in immune thrombocytopenia.

Authors:  A Salama; C Mueller-Eckhardt; V Kiefel
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

5.  Early relapses after plasma exchange in acute inflammatory polyradiculoneuropathy.

Authors:  P O Osterman; J Fagius; J Säfwenberg; B G Danielsson; B Wikström
Journal:  Lancet       Date:  1986-11-15       Impact factor: 79.321

6.  Limited relapse in Guillain-Barré syndrome after plasma exchange.

Authors:  A E Ropper; J W Albert; R Addison
Journal:  Arch Neurol       Date:  1988-03

7.  Demyelination induced by serum from patients with Guillain-Barré syndrome.

Authors:  B M Harrison; L A Hansen; J D Pollard; J G McLeod
Journal:  Ann Neurol       Date:  1984-02       Impact factor: 10.422

8.  Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation.

Authors:  C L Koski; R Humphrey; M L Shin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

9.  Treatment of Guillain-Barré syndrome with high-dose gammaglobulin.

Authors:  R P Kleyweg; F G van der Meché; J Meulstee
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

10.  Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome.

Authors:  C L Koski; E Gratz; J Sutherland; R F Mayer
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422
View more
  2 in total

1.  Intravenous immunoglobulins in severe Guillian-Barre syndrome in childhood.

Authors:  Preeti Shanbag; Cynthia Amirtharaj; Ashish Pathak
Journal:  Indian J Pediatr       Date:  2003-07       Impact factor: 1.967

2.  Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study.

Authors:  R Korinthenberg; J S Mönting
Journal:  Arch Dis Child       Date:  1996-04       Impact factor: 3.791
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.